Start a live chat
1-800-870-4800
What bioavailability means —
and why it matters
when the destination is a cell.
A molecule that cannot reach its destination is a molecule that cannot do its work. Bioavailability — the proportion of a substance that enters circulation and reaches the tissues where it is needed — is one of the most consequential and least discussed dimensions of how the body handles anything it is given to absorb. For NMN, the journey from consumption to cellular NAD+ involves several distinct biological checkpoints, each of which the molecule must navigate successfully.
I
The gap between taking something
and the body actually using it.
Bioavailability is one of those concepts that sounds technical but describes something immediately intuitive: not everything you consume reaches the place it needs to go. The path from a molecule entering the mouth to that molecule performing its intended function inside a cell involves transit through the digestive system, absorption across the intestinal wall, entry into the bloodstream, transport to tissues, uptake across cell membranes, and — in many cases — enzymatic conversion before the final active form is present and functioning. At each step, some fraction of the original molecule is lost, degraded, converted into something else, or simply fails to cross the biological barrier it encounters.
For many substances, this attrition is manageable. The body has evolved efficient uptake mechanisms for the nutrients and compounds it has always encountered in food, and for water-soluble vitamins and small molecules that cross membranes freely, bioavailability is often reasonably high. But for molecules that are larger, more structurally complex, or less familiar to the digestive system's transport machinery — the question of how much actually arrives at the target tissue, in the form needed, is not trivial.
NMN sits in an interesting position in this landscape. It is a nucleotide — a class of molecules not typically absorbed intact across the intestinal wall. Early questions about whether orally administered NMN could survive the gastrointestinal tract, enter the bloodstream in usable form, and ultimately contribute to intracellular NAD+ levels were genuine scientific questions, not rhetorical ones. The evidence that has accumulated — beginning with the first human pharmacokinetic studies — has largely confirmed that NMN is absorbed and converted to NAD+ metabolites in the bloodstream. But the questions around how efficiently, and whether different delivery approaches change that picture, remain active areas of investigation.
A molecule that cannot
reach its destination
is a molecule that cannot
do its work.
The Absorption Journey
From consumption to cell —
the checkpoints NMN must pass.
Each stage in the absorption sequence represents both a biological necessity and a potential point of loss. Understanding the journey clarifies why delivery format matters — and what the body is actually doing between the moment of consumption and the moment NAD+ levels in tissue change.
Surviving the digestive environment before absorption can begin
Before NMN can be absorbed, it must survive the chemical environment of the stomach and small intestine — acidic pH, digestive enzymes, and the microbial landscape of the gut. Early research raised questions about whether NMN, as a nucleotide, might be broken down in the gut before absorption. More recent work — including the identification of a specific intestinal transporter for NMN (Slc12a8) — has shown that at least some NMN can be absorbed intact, though the efficiency of this process and whether it accounts for most of the observed NAD+ increase remains an open question that continues to be studied.
The intestinal wall as gatekeeper — what crosses and what does not
The intestinal epithelium is selective about what it allows to pass into circulation. Small, lipid-soluble molecules cross relatively freely. Larger, hydrophilic molecules like NMN rely on specific transport proteins — and the capacity of those transporters can be saturated at higher doses. The discovery of the Slc12a8 transporter as a dedicated NMN uptake mechanism was significant precisely because it showed the intestinal wall is not simply a passive barrier for this molecule. Whether supplemental NMN primarily crosses as NMN or is first converted to nicotinamide in the gut and then reconverted intracellularly remains an area of active investigation in the pharmacokinetics literature.
Reaching the right tissues — not all organs receive equal distribution
Once in the bloodstream, NMN — or the NAD+ metabolites it has been converted into — must be distributed to the tissues where NAD+ restoration matters most. Human pharmacokinetic studies have confirmed that oral NMN produces measurable increases in NAD+ metabolites in blood within hours of consumption. What those blood measurements mean for intracellular NAD+ in specific tissues — muscle, brain, liver, heart — is a more complex question, because the relationship between circulating NAD+ metabolites and intracellular NAD+ is not direct. Tissue-specific bioavailability remains one of the more nuanced dimensions of NMN pharmacology.
The final crossing — into the cell and toward the NAD+ pool
The body's NAD+ biosynthesis machinery operates inside cells — meaning that precursors like NMN are converted to NAD+ intracellularly, through the enzymatic steps that take place within the relevant cellular compartments. Once NMN or its metabolic derivatives reach cells, NMNAT completes the conversion to NAD+ inside those compartments. The efficiency of this final step — and whether supplemental NMN arrives at the cell in a form that NMNAT can readily act on — is where the bioavailability question ultimately lands. It is also where delivery format has its most direct potential influence on the overall process.
II
Why delivery format
enters the conversation.
The bioavailability question for NMN is not simply academic. It is the practical reason why different delivery formats have been developed, studied, and debated in the NMN supplement space — and why terms like "liposomal NMN" and "sublingual NMN" have moved from specialist language into common usage among people seriously engaged with longevity nutrition.
The core rationale behind alternative delivery formats is consistent: if standard oral NMN faces absorption barriers in the gastrointestinal tract — whether due to enzymatic breakdown, transporter saturation, or conversion to other forms before reaching cells — then formats that either bypass those barriers or protect the molecule during transit represent a different approach to the absorption process. Whether those structural differences translate into meaningfully different outcomes in the human body is the question the delivery format literature is still working to answer with the rigor the question deserves.
What is clear from the existing evidence is that standard oral NMN does reach the bloodstream and does produce measurable increases in NAD+ metabolites — the pharmacokinetic studies establish that. The open question is not whether oral NMN is absorbed, but whether different delivery approaches produce different absorption profiles, different tissue distributions, or different intracellular NAD+ outcomes. That question is part of an active and still-developing area of NMN pharmacology, and the honest answer is that the comparative data is still being built.
Delivery Format Overview
The main NMN delivery approaches —
what each one is and how it works.
These are descriptions of delivery mechanisms — not comparisons of efficacy or claims about any specific product. The science of how each format affects absorption and bioavailability continues to develop.
Format 01
Standard oral capsule or powder
The most common and most studied delivery format. NMN in powder or capsule form is swallowed and exposed to the full gastrointestinal absorption process — stomach acid, digestive enzymes, intestinal transport. Human pharmacokinetic data confirms this route produces measurable NAD+ metabolite increases in blood. The efficiency of absorption and the tissue-specific distribution of what is absorbed remains the subject of ongoing investigation.
The format for which the most human pharmacokinetic data currently exists.
Format 02
Sublingual NMN
Sublingual administration places NMN under the tongue, where the thin mucous membrane allows direct absorption into the bloodstream via the sublingual veins — bypassing the gastrointestinal tract and first-pass liver metabolism. In principle, this route bypasses the gastrointestinal tract and first-pass liver metabolism. In practice, the amount of NMN that can be delivered sublingually in a single dose is limited, and the comparative bioavailability data versus standard oral forms is still developing.
Designed to bypass gastrointestinal processing — comparative data still emerging.
Format 03
Liposomal NMN
Liposomal delivery encapsulates NMN within phospholipid bilayer vesicles — structures whose outer membrane is chemically similar to cell membranes. The rationale is that liposomes can protect the encapsulated molecule from degradation in the gastrointestinal environment and may facilitate cellular uptake through membrane fusion. Liposomal delivery is an established pharmaceutical technology used for a range of compounds. Its application to NMN is a more recent development, and the specific bioavailability data for liposomal NMN continues to be generated.
An established pharmaceutical delivery technology applied to NMN — ongoing bioavailability investigation.
Delivery Approach Comparison
Standard oral vs. liposomal —
how the two approaches differ in principle.
Direct exposure to the gastrointestinal absorption pathway.
NMN exposed directly to stomach acid and digestive enzymes
Intestinal absorption via the Slc12a8 transporter and other mechanisms
Some fraction may be converted to nicotinamide before crossing the gut wall
Well-studied format — the most human pharmacokinetic data exists for this route
Confirmed to produce measurable NAD+ metabolite increases in blood
Tissue-specific distribution and intracellular outcomes continue to be studied
NMN encapsulated in phospholipid vesicles designed to protect during transit.
NMN protected within a phospholipid bilayer during gastrointestinal transit
Liposome structure may reduce degradation before intestinal absorption
Membrane fusion mechanism may facilitate cellular uptake more directly
Established delivery technology from pharmaceutical applications
Applied to NMN more recently — specific bioavailability data still developing
The theoretical absorption advantages are the subject of active investigation
Bioavailability in Numbers
What the absorption picture
looks like in measurable terms.
4
Distinct biological stages between NMN consumption and intracellular NAD+ production
GI transit, intestinal wall crossing, bloodstream distribution, and cellular uptake each represent a stage where absorption can be complete, partial, or redirected through conversion to other metabolites. The complexity of this journey — across four distinct biological environments — is why bioavailability is not a simple yes or no for any orally administered molecule of NMN's complexity.
Hours
Time to measurable NAD+ metabolite increase in blood after oral NMN — confirmed in human pharmacokinetic studies
Human pharmacokinetic studies have documented measurable increases in NAD+ metabolites in the bloodstream within hours of oral NMN administration — confirming that the molecule does successfully navigate the absorption process in biologically meaningful quantities. The precise time course varies by dose, individual metabolism, and measurement methodology, and continues to be refined in the clinical literature.
1
Dedicated intestinal NMN transporter identified — Slc12a8 — suggesting the gut recognizes NMN specifically
The identification of Slc12a8 as a specific intestinal transporter for NMN was a meaningful finding in the bioavailability story — it indicated that the gut has a dedicated mechanism for NMN uptake rather than relying on non-specific passive diffusion. The functional significance of this transporter in human NMN absorption, and its relationship to the different forms NMN may take during GI transit, remains an active area of investigation.
III
What bioavailability means
for how NMN is approached at Codeage.
The bioavailability question is not a reason for uncertainty about NMN — the evidence that it is absorbed and produces measurable changes in NAD+ metabolites in human blood is established. It is, rather, the reason why delivery format is a considered dimension of how NMN is formulated rather than an afterthought. The journey from consumption to intracellular NAD+ involves multiple biological barriers, and the efficiency of that journey has direct implications for how much of a given dose actually reaches the cellular environment where it is needed.
Liposomal delivery technology — used across a range of pharmaceutical and nutraceutical applications — represents one approach to the absorption process, designed around protecting the molecule during GI transit and working through the structural properties of phospholipid vesicles. Whether the characteristics of liposomal NMN translate into meaningfully different outcomes in human tissue is a question the emerging data continues to address. The honest position is that the delivery science, like the broader NMN biology, is still being refined — and what we understand about the optimal approach to NMN bioavailability today will likely be clearer and more precisely characterised as the field continues to generate data.
That evolving picture is exactly the context in which Cellular Longevity — Pillar 03 of The Longevity Code — thinks about NMN formulation. For the foundational biology of how NMN moves through the body's own biosynthesis system, the biosynthesis article and the structural difference article both provide relevant context for understanding what NMN is and why its delivery matters.
The evidence that NMN is absorbed
is established.
The question is how efficiently —
and whether delivery format
changes that answer.
Codeage · Pillar 03 · Cellular Longevity
Built for the
cellular long game.
Cellular Longevity is Pillar 03 of The Longevity Code — the dimension of the system built around NAD+ biology, mitochondrial health, and the science of cellular aging.
Explore Cellular Longevity →
